Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM [Phase 2]

View source ↗

Summary

Novartis' Phase 2 trial of subcutaneously administered MBL949 in obese participants (with or without type 2 diabetes mellitus) was terminated, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• MBL949

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Obesity | Phase 2 | Status: TERMINATED | Results posted: 2024-05-31